In particular, MDS/AML cell lines with mutations in the splicing factors U2AF1 and SF3B1 had higher expression of IRAK4-L and inhibition of IRAK-4 abrogated leukemic growth more effectively (65). This evidence concerns the gene IRAK4 and acute myeloid leukemia.